Determining the risk factor profile and biology of colorectal cancer in Nigeria
确定尼日利亚结直肠癌的危险因素概况和生物学
基本信息
- 批准号:10053881
- 负责人:
- 金额:$ 37.87万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-08-01 至 2024-04-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAfricaAfrica South of the SaharaAfricanAfrican AmericanAlcohol consumptionAtlas of Cancer Mortality in the United StatesBRAF geneBiologyBlood specimenCancer BiologyCancer BurdenCancer ControlCancer EtiologyCessation of lifeCollaborationsColorectal CancerCountryDNA Sequence AlterationDataData SetDetectionDiagnosisDietDietary HistoryDiseaseEarly DiagnosisEnrollmentEnvironmentEnvironmental ExposureEtiologyEuropeanEvidence based interventionExposure toFrequenciesFutureGenomicsGerm-Line MutationHealthHealth Promotion and EducationHereditary Nonpolyposis Colorectal NeoplasmsHigh PrevalenceHigh-Frequency Microsatellite InstabilityIncidenceIncomeInfectious AgentInfrastructureInheritedInterventionKRAS2 geneKnowledgeLifeLife StyleMalignant NeoplasmsMapsMedical HistoryMedical centerMemorial Sloan-Kettering Cancer CenterMicrosatellite InstabilityMolecularMorbidity - disease rateMulticenter StudiesMutationNigeriaNigerianObesityOncogenesOncology GroupOutcomeOverweightParticipantPatientsPatternPersonsPopulationPopulation StudyPreventionProspective cohort studyQuestionnairesResearchResourcesRisk FactorsSavingsSmokingSomatic MutationSubgroupTestingThe Cancer Genome AtlasWorkWorld Health Organizationbasebiobankcancer preventionclinical databaseclinically actionableclinically significantcolon cancer patientscolorectal cancer preventioncolorectal cancer riskcombatcost effectivecost efficientdeep sequencingearly onseteffective therapyevidence basegenomic profileshigh riskimprovedinsightmortalitynoveloutcome forecastpopulation basedprospectiverecruitreproductivescreeningstatisticstrendtumor
项目摘要
ABSTRACT
Colorectal cancer (CRC) incidence and mortality are rapidly rising in sub-Saharan Africa; CRC is now the 4th
most common cancer in the World Health Organization-Africa region. This rising burden is mirrored in Nigeria,
where more than half of patients die within one year of diagnosis. These statistics highlight the need for cost-
effective, evidence-based prevention, screening, and treatment interventions in this limited-resource region.
However, an understanding of risk factors and the genomic landscape of CRC in this population is needed to
inform such efforts. Through the African Research Group for Oncology (ARGO), we have established
infrastructure and local scientific partnerships for novel cancer studies in Nigeria. We have an existing clinical
database and a biobank of tumor and matched normal blood specimens from 490 prospectively enrolled Nigerian
CRC patients. Data suggest Nigerian CRCs may possess distinct etiology. Overweight/obesity, the most
common CRC risk factor in the US, is ~3-fold less prevalent in Nigeria. Similarly, other established risk factors,
such as smoking and alcohol use, are half as frequent in Nigeria, suggesting other common endemic factors
(e.g., infectious agents, environment, or diet) may drive CRCs in Nigeria. Furthermore, our pilot sequencing data
from 65 Nigerian tumors show clinically significant differences vs. US patients. For instance, tumors from
Nigerian patients had ~2-fold fewer somatic APC mutations, more KRAS mutations, and ~3-fold higher
prevalence of high microsatellite instability. We also found ~3-fold higher prevalence of hereditary Lynch
syndrome in Nigerian patients. To extend these preliminary analyses and further define CRC etiology in Nigeria,
we propose the first multi-center study of CRC risk factors and genomics in sub-Saharan Africa. We will use
ARGO infrastructure to conduct a large, cost-efficient, opportunistic study to: 1) Identify risk factors for CRC
in Nigeria. We will recruit 600 CRC cases matched to 1,200 cancer-free population-based controls. Participants
will complete an existing questionnaire developed by our group for use in Nigeria to assess demographic,
anthropometric, reproductive, lifestyle, dietary, and medical history. And 2) Characterize molecular features of
CRC tumors in Nigeria. We will perform targeted deep sequencing of 468 established cancer genes in matched
tumor/blood samples from a subset of 360 CRC cases enrolled in Aim 1. After combining with existing data from
65 patients (N=425), we will map cancer genes altered by somatic or germline mutations in Nigerian patients
and compare our data to large existing US datasets. These aims will provide a better understanding of the risk
factor and genomic features of CRC in a West African population – a first step towards improving prevention,
screening, and treatment of the disease in this understudied population. In addition, the etiological insights
gained through the work proposed have high potential applicability to understudied US populations with poor
CRC outcomes, such as African American and early-onset CRC patients.
抽象的
撒哈拉以南非洲的结直肠癌(CRC)发病率和死亡率迅速上升; CRC现在是第四名
世界卫生组织 - 非洲地区最常见的癌症。这种上升的烧伤在尼日利亚镜像,
在诊断后的一年内,超过一半的患者死亡。这些统计数据凸显了需要成本的
有效的,基于证据的预防,筛查和治疗干预措施。
但是,需要了解该人群中CRC的危险因素和基因组景观
告知这样的努力。通过非洲肿瘤学研究小组(ARGO),我们建立了
尼日利亚新型癌症研究的基础设施和本地科学伙伴关系。我们有现有的临床
数据库和肿瘤的生物库,并匹配490名尼日利亚人的490个正常血样
CRC患者。数据表明尼日利亚CRC可能具有不同的病因。超重/肥胖,最多
在美国,常见的CRC风险因素在尼日利亚的普遍性降低了约3倍。同样,其他已建立的风险因素,
在尼日利亚,吸烟和饮酒等频率频繁,这表明其他常见的内在因素
(例如,传染剂,环境或饮食)可能在尼日利亚驱动CRC。此外,我们的试点测序数据
与美国患者相比,从65种尼日利亚肿瘤显示出临床显着差异。例如,来自
尼日利亚患者的体细胞APC突变减少了约2倍,KRAS突变更多,高约3倍
高卫星不稳定性的患病率。我们还发现遗传林奇的患病率高约3倍
尼日利亚患者的综合征。为了扩展这些初步分析并进一步定义了尼日利亚的CRC病因,
我们建议在撒哈拉以南非洲的CRC风险因素和基因组学首次多中心研究。我们将使用
Argo基础设施进行大型,具有成本效益的机会性研究至:1)确定CRC的风险因素
在尼日利亚。我们将招募600例CRC病例,匹配1,200个基于人群的对照。参与者
将完成我们小组在尼日利亚使用的现有调查表,以评估人口统计学,
人体测量学,生殖,生活方式,饮食和病史。 2)表征分子特征
尼日利亚的CRC肿瘤。我们将对匹配的468个已建立的癌症基因进行有针对性的深度测序
来自AIM 1的360例CRC病例的子集的肿瘤/血液样本。与现有数据结合后
65例患者(n = 425),我们将绘制尼日利亚患者的体细胞或种系突变改变的癌症基因
并将我们的数据与大型现有的美国数据集进行比较。这些目标将更好地了解风险
CRC在西非人口中的因素和基因组特征 - 改善预防的第一步,
筛查和治疗该疾病的人群。此外,病因见解
通过拟议的工作获得具有很高的潜在适用性,可以理解贫困的美国人群
CRC结果,例如非裔美国人和早期发作的CRC患者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
OLUSEGUN ISAAC ALATISE其他文献
OLUSEGUN ISAAC ALATISE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('OLUSEGUN ISAAC ALATISE', 18)}}的其他基金
Expanding cancer research capacity in Nigeria with team science
通过团队科学扩大尼日利亚的癌症研究能力
- 批准号:
10438142 - 财政年份:2022
- 资助金额:
$ 37.87万 - 项目类别:
Expanding cancer research capacity in Nigeria with team science
通过团队科学扩大尼日利亚的癌症研究能力
- 批准号:
10588180 - 财政年份:2022
- 资助金额:
$ 37.87万 - 项目类别:
Determining the risk factor profile and biology of colorectal cancer in Nigeria
确定尼日利亚结直肠癌的危险因素概况和生物学
- 批准号:
10630075 - 财政年份:2020
- 资助金额:
$ 37.87万 - 项目类别:
Collecting whole genome sequence data to enhance the value of the first multi-center study of colorectal cancer risk factors and biology in Nigeria
收集全基因组序列数据,以提高尼日利亚首个结直肠癌危险因素和生物学多中心研究的价值
- 批准号:
10629701 - 财政年份:2020
- 资助金额:
$ 37.87万 - 项目类别:
Mentoring a Nigerian junior investigator with a mixed-methods analysis of barriers to colorectal cancer presentation in Nigeria
指导一名尼日利亚初级研究员对尼日利亚结直肠癌表现的障碍进行混合方法分析
- 批准号:
10623852 - 财政年份:2020
- 资助金额:
$ 37.87万 - 项目类别:
Determining the risk factor profile and biology of colorectal cancer in Nigeria
确定尼日利亚结直肠癌的危险因素概况和生物学
- 批准号:
10398938 - 财政年份:2020
- 资助金额:
$ 37.87万 - 项目类别:
Determining the risk factor profile and biology of colorectal cancer in Nigeria
确定尼日利亚结直肠癌的危险因素概况和生物学
- 批准号:
10227199 - 财政年份:2020
- 资助金额:
$ 37.87万 - 项目类别:
Point of care, real-time urine metabolomics test to diagnose colorectal cancers and polyps in low- and middle-income countries
护理点实时尿液代谢组学测试可诊断低收入和中等收入国家的结直肠癌和息肉
- 批准号:
9221852 - 财政年份:2017
- 资助金额:
$ 37.87万 - 项目类别:
Point of care, real-time urine metabolomics test to diagnose colorectal cancers and polyps in low- and middle-income countries
护理点实时尿液代谢组学测试可诊断低收入和中等收入国家的结直肠癌和息肉
- 批准号:
10173098 - 财政年份:2017
- 资助金额:
$ 37.87万 - 项目类别:
Point of care, real-time urine metabolomics test to diagnose colorectal cancers and polyps in low- and middle-income countries
护理点实时尿液代谢组学测试可诊断低收入和中等收入国家的结直肠癌和息肉
- 批准号:
10378649 - 财政年份:2017
- 资助金额:
$ 37.87万 - 项目类别:
相似国自然基金
非洲爪蟾IV型干扰素IFN-upsilon在不同发育阶段的抗病毒功能研究
- 批准号:32303043
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
非洲猪瘟病毒pS273R通过切割G3BP1调控宿主应激颗粒形成的机制
- 批准号:32302893
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于非洲猪瘟病毒pS273R蛋白泛素-蛋白酶体降解途径阻抑机制理性设计其特异性蛋白水解靶向嵌合体的研究
- 批准号:32373044
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
非洲猪瘟病毒B475L蛋白靶向LMP2抑制抗原递呈的分子机制
- 批准号:32302894
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
抗体依赖性增强效应介导非洲猪瘟病毒致病的分子机制
- 批准号:32373024
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
相似海外基金
Caring for Providers to Improve Patient Experience (CPIPE) Study
关爱医疗服务提供者以改善患者体验 (CPIPE) 研究
- 批准号:
10556284 - 财政年份:2023
- 资助金额:
$ 37.87万 - 项目类别:
Mechanistic characterization of vaginal microbiome-metabolome associations and metabolite-mediated host inflammation
阴道微生物组-代谢组关联和代谢物介导的宿主炎症的机制特征
- 批准号:
10663410 - 财政年份:2023
- 资助金额:
$ 37.87万 - 项目类别:
Couples Advancing Together for Safer Conception (CAT-SC): A couples’-based intervention to improve engagement in sexual and reproductive health services for mobile fisherfolk in Kenya
夫妻共同推进安全受孕 (CAT-SC):基于夫妻的干预措施,旨在提高肯尼亚流动渔民对性健康和生殖健康服务的参与度
- 批准号:
10618411 - 财政年份:2023
- 资助金额:
$ 37.87万 - 项目类别:
Artificial Intelligence assisted echocardiography to facilitate optimal image extraction for congenital heart defects diagnosis in Sub-Saharan Africa
人工智能辅助超声心动图促进撒哈拉以南非洲先天性心脏缺陷诊断的最佳图像提取
- 批准号:
10710681 - 财政年份:2023
- 资助金额:
$ 37.87万 - 项目类别:
P-KIDs CARE: An Intervention to Address Health Systems Delays to Care for Injured Children in Tanzania
P-KIDs CARE:解决坦桑尼亚卫生系统延误照顾受伤儿童的干预措施
- 批准号:
10722628 - 财政年份:2023
- 资助金额:
$ 37.87万 - 项目类别: